Generic Price Competition For Specialty Drugs: Too Little, Too Late?
- 1 May 2018
- journal article
- research article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 37 (5), 738-742
- https://doi.org/10.1377/hlthaff.2017.1684
Abstract
The case of generic imatinib demonstrates several potential barriers to effective generic price competition for specialty prescription drugs, including fewer market entrants, smaller-than-expected price reductions, shifts in prescribing toward more expensive brand-name treatments, and limited uptake of the generic product.Keywords
This publication has 11 references indexed in Scilit:
- Journey of Generic Imatinib: A Case Study in Oncology Drug PricingJournal of Oncology Practice, 2017
- Generic Drug Approvals Since the 1984 Hatch-Waxman ActJAMA Internal Medicine, 2016
- Role of the FDA in Affordability of Off-Patent PharmaceuticalsPublished by American Medical Association (AMA) ,2016
- Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EUAnnals of Hematology, 2015
- The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML expertsPublished by American Society of Hematology ,2013
- The Consequences of Requesting “Dispense as Written”American Journal Of Medicine, 2011
- Generic competition and market exclusivity periods in pharmaceuticalsManagerial and Decision Economics, 2007
- Generic Competition in the US Pharmaceutical IndustryInternational Journal of the Economics of Business, 2006
- Entry Decisions in the Generic Pharmaceutical IndustryThe RAND Journal of Economics, 1999